Cyclacel To Present At BIO CEO & Investor Conference

Dundee, UK - 18 February 2004 - Cyclacel Limited, the UK-based biopharmaceutical company, announced today that it will be presenting in three separate sessions at the BIO CEO & Investor Conference taking place at New York 's Waldorf Astoria Hotel (23-25 February 2004). Cyclacel's Chief Executive Officer Spiro Rombotis will present Cyclacel's clinical and preclinical stage drug portfolio on Wednesday 25th February between 14:30 and 15:00 . The presentation will be available on the Company's website for 30 days following the event.

In addition Cyclacel was invited to present in two focus sessions entitled: “Biomarkers: An Emerging & Important Tool for Lessening Drug Development Risk” (Tuesday 24th February, 15:30-17:00 ) and “Pathways Based Drug Discovery: Using Pathway Intersections to Optimize Drug Intervention” (Wednesday 25th February, 09:30-11:00 ).

About Cyclacel ( www.cyclacel.com )
Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, state-of-the-art RNAi functional genomics, chemogenomics and clinical biomarker technologies to rapidly deliver new drugs. The Company has nine research and development programs underway. Most advanced is CYC202, a Cyclin Dependent Kinase (CDK) inhibitor, in Phase II trials for breast and lung cancer. CYC202 has completed Phase I trials in Europe with evidence of potential clinical benefit and is also being explored for use in glomerulonephritis, an inflammatory disease associated with kidney cell proliferation. CYC682, a nucleoside analogue, has completed Phase I trials in the USA with evidence of potential clinical benefit and was shown in preclinical tests to be superior to the leading nucleoside analogue gemcitabine. Cyclacel has entered into corporate alliances with AstraZeneca, CV Therapeutics, Lorus, Sankyo and a top 5 pharmaceutical major all in the oncology field. Cyclacel has raised since inception a total of $123 million (£67m) in private equity.

DISCLAIMER: Cyclacel cautions you that statements in this document that are not describing historical facts may be forward-looking statements that should not be regarded as a representation by Cyclacel that any of its plans will materialize. Actual results may differ materially from those set forth herein due to the risks and uncertainties inherent in Cyclacel's business including, without limitation, statements about: the progress and timing of its clinical trials; dependence on others or difficulties or delays in clinical development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; expanding into other disease indications and its ability to obtain additional financing when needed and on reasonable terms to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement. Other than its obligations to its shareholders, Cyclacel undertakes no obligation to revise or update forward-looking statements, whether as a result of new information, future events or otherwise to reflect events or circumstances after the date hereof.

Notes to Editors: Spiro Rombotis, 45, joined August 1997. Has 21 years of experience with pharmaceutical and biotech companies. Previously Vice President, International Operations & Business Development, Managing Director, Europe and Director Japanese joint venture, The Liposome Company, Inc.; Vice President, Pharmaceuticals, Central & Eastern Europe and Director International Marketing, Bristol-Myers Squibb Company; Head European Marketing and Sales, Head Corporate Development, Centocor, Inc.; Business Development, Novartis AG. BA, Williams College , USA . MBA and Master's degree in Hospital Management with honors, Kellogg Graduate School of Management, where he serves on the Advisory Board, Kellogg Center for Biotechnology.

© 2004 - Cyclacel Limited . Cyclacel ® , Fluorescience ® , Penetratin ® and Polgen ® are registered trademarks.